Preview

Современная ревматология

Расширенный поиск

Персонифицированная медицина: предикторы эффективности терапии генно-инженерными биологическими препаратами при ревматоидном артрите

https://doi.org/10.14412/1996-7012-2017-2-4-17

Полный текст:

Аннотация

Одно из наиболее существенных достижений ревматологии последних десятилетий – внедрение в клиническую практику генно- инженерных биологических препаратов (ГИБП). В то же время стоимость такого лечения очень высока, поэтому большой интерес может представлять разработка методов прогнозирования результатов предполагаемой терапии. В ряде исследований изучаются факторы, определяющие ответ на ГИБП. Публикации, посвященные данной проблеме, очень неоднородны: используются данные, полученные в разных популяциях, а также различные методы исследований и критерии оценки эффективности терапии. В качестве потенциальных предикторов эффективности ГИБП рассматриваются особенности течения заболевания, конституциональные параметры пациента, генетические факторы, наличие коморбидной патологии или сопутствующая терапия. Не исключено, что оптимальный результат может быть получен на основании комплексной оценки этих факторов.

 

Об авторах

М. А. Котовская
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Н. Ю. Никишина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Ю. А. Олюнин
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия


Литература

1. Балабанова РМ, Эрдес ШФ. Распространенность ревматических заболеваний в России в 2012-2013 гг. Научно-практическая ревматология. 2015;53(2):120-4. [Balabanova RM, Erdes SF. The incidence and prevalence of rheumatic diseases in Russia in 2012-2013. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):120-4 (In Russ.)]. doi:10.14412/1995-4484-2015-120-124].

2. Насонов ЕЛ, редактор. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2010. С. 290-2. [NasonovEL. Revmatologiya: natsionalnoe rukovodsvo [Rheumatology. A national guide].Moscow: GEOTAR-Media; 2010. P. 290-2].

3. Насонов ЕЛ. Фармакотерапия ревматоидного артрита – взгляд в 21 век. Клиническая медицина. 2005;(6):8-12. [Nasonov EL. Pharmacotherapy of rheumatoid arthritis: the 21st century. Klinicheskaya Meditsina. 2005;(6):8-12. (In Russ.)].

4. Van Schouwenburg P, Krieckaert CL, Rispens T, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013 Oct;72(10):1680-6. doi: 10.1136/annrheumdis-2012-202407. Epub 2013 Jan 7.

5. http://www.legeneraliste.fr/layont/ Rub_FMC/art.21862

6. Cremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicenter real life prospective study. Ann Rheum Dis. 2013 Jun;72(6): 858-62. doi: 10.1136/annrheumdis-2012- 201456. Epub 2012 Jul 13.

7. Eriksson JK, Wallman JK, Miller H, et al. Infliximab versus conventional combination treatment and 7-year work loss in early RA. Results of the randomized Swefot Treal. Arthr Care Res (Hoboken). March 2016;25.

8. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006 Dec;45(12): 1558-65. Epub 2006 May 16.

9. Kleinert S, Tony HP, Krause A, et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int. 2012 Sep;32(9):2759-67. doi: 10.1007/s00296-011- 2033-5. Epub 2011 Aug 6.

10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trialof combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26-37.

11. Marks JL, Holroyd CR, Dimitrov BD, et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy? Arthritis Care Res (Hoboken). 2015 May;67(6): 746-53. doi: 10.1002/acr.22552.

12. Ornbjerg LM, Ostergaard M, Boyesen P, et al. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. J Rheumatol. 2014 Dec;41(12): 2352-60. doi: 10.3899/jrheum.131299. Epub 2014 Oct 1.

13. Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohort. Arthritis Rheum. 2011 Jan;63(1):26-36. doi: 10.1002/art.27758.

14. Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012 Feb;41(1):1-9. doi: 10.3109/ 03009742.2011.599073. Epub 2011 Nov 28.

15. Savioli C, Silva CA, Ching LH, et al. Dental and facial characteristics of patients with juvenile idiopathic arthritis. Rev Hosp Clin Fac Med Sao Paulo. 2004 Jun;59(3):93-8. Epub 2004 Jul 28.

16. Savioli C, Ribeiro AC, Fabri GM, et al. Persistent periodontal disease hampers antitumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol. 2012 Jun;18(4):180-4. doi: 10.1097/RHU. 0b013e31825828be.

17. Iannone F, Fanizzi R, Notarnicola A, et al. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. J Joint Bone Spine. 2015 May;82(3):187-91. doi: 10.1016/j.jbspin.2014.12.006. Epub 2015 Jan 22.

18. Wolbink GJ, Voskuy AE, Lems W, et al. Relationship between serum trough infliximab levels, pretreatment C-reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005 May;64(5):704-7. Epub 2004 Oct 14.

19. Maini R, Taylor P, Paleolog E, et al. Antitumor necrosis antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis. 1999;58 suppl1:56-60.

20. Hyrich KL, Watson KD, Silman A, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Register. Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

21. Lequerre T, Jouen F, Brazier M, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford). 2007 Mar;46(3):446-53. Epub 2006 Aug 9.

22. Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum. 2005 Jan;52(1):42-8.

23. Kristensen LE, Kapetanovic MC, Gulfe A, et al.Predictors of response to anti-TNFalpha therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008 Apr;47(4):495-9. doi: 10.1093/ rheumatology/ken002. Epub 2008 Mar 3.

24. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007 Mar;66(3):302-7. Epub 2006 Nov 1.

25. Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol. 2006 Mar;33(3):497-500.

26. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ ard.2007.084715. Epub 2008 Mar 28.

27. Canhao H, Rodriguez AM, Mourao AF, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012 Nov;51(11): 2020-6. doi: 10.1093/rheumatology/kes184. Epub 2012 Jul 28.

28. Klassen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab iin rheumatoid arthritis: an exploratory study. Rheumatology (Oxford). 2011 Aug;50(8):1487-93. doi: 10.1093/ rheumatology/ker010. Epub 2011 Mar 30.

29. Hodkinson B, Musenge E, Ally M, et al. Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis. Clin Rheumatol. 2012 Apr;31(4):613-9. doi: 10.1007/s10067-011-1900-5.

30. Alessandri C, Bombardieri M, Papa N, et al.Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004 Oct;63(10): 1218-21.

31. Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Jan;65(1):35-9. Epub 2005 Jun 23.

32. Lv Q, Yin Y, Li X, et al.The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a metaanalysis. PLoS One. 2014 Feb 27;9(2):e89442. doi: 10.1371/journal.pone.0089442. eCollection 2014.

33. Couderc M, Mathieu S, Pereira B, et al. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken). 2013 April;65(4):648-52. Doi: 10.1002/acr.21865.

34. http://www.sciencedirect.com/science/ journal/09925945/23/465

35. Gardette A, Ottaviani S, Tubach F, et al. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine. 2014 Oct;81(5):416-20. doi: 10.1016/j.jbspin.2014. 06.001. Epub 2014 Jul 3.

36. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiviness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011 Sep;70(9): 1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

37. Drynda S, Kuhne C, Kekow J. Soluble tumor necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis. 2002 Mar;61(3):254-6.

38. Chopin F, Garnero P, le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Mar; 67(3):353-7. Epub 2007 Jul 20.

39. Marotte H, Pallot-Prades B, Grange L, et al. A 1-year case-control sudy in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9(3):R61.

40. Marotte H, Gineyts E, Miossec P, et al. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis. 2009 Jul;68(7): 1197-200. doi: 10.1136/ard.2008.096057. Epub 2008 Aug 19.

41. Александрова ЕН, Авдеева АС, Лукина ГВ и др. Клинико-иммунологические эффекты анти-В-клеточной терапии у больных ревматоидным артритом. Научно-практическая ревматология. 2012;(50) 1:14-21. [Aleksandrova EN, Avdeeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. NauchnoPrakticheskayaRevmatologiya = Rheumatology Science and Practice. 2012;(50)1:14-21 (In Russ.)]. doi: 10.14412/1995-4484-2012-498

42. Авдеева АС, Александрова ЕН, Новиков АА и др. Иммунологические предикторы эффекта анти-В-клеточной терапии при ревматоидном артрите. Клиническая и лабораторная диагностика. 2014;(3): 48-52. [Avdeeva AS, Aleksandrova EN, Novikov AA, et al. The immunologic predictors of effect anti-B-cell therapy under rheumatoid arthritis. Klinicheskaya i laboratornaya diagnostika. 2014;(3):48-52 (In Russ.)].

43. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015 Aug;29(4): 241-58. doi: 10.1007/s40259-015-0134-5.

44. Cuchanovich M, Soto I, Edwardes M, et al. Tumour necrosis factor (TNF) alpha- 308G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2006 Nov-Dec;35(6):435-40.

45. Marotte H, Arnaud B, Diasparra J, et al. Association between the level of circulating bioactive tumor necrosis factor alpha and tumor necrosis factor alpha gene polymorphism at 308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2008 May;58(5):1258-63. doi: 10.1002/art.23430.

46. Gavrila BL, Ciofu C, Stoica V, et al. The efficiency of biologic therapy in a group of patients with rheumatoid arthritis. J Med Life. 2015 Jan-Mar;8(1):79-84.

47. Sekiguchi N, Kawauchi S, Furuya T, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford). 2008 Jun;47(6):780-8. doi: 10.1093/rheumatology/ken083. Epub 2008 Apr 3.

48. Gonzalez-Alvaro I, Ortiz AM, Tomero EG, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patirnts treated with TNF antagonists. Ann Rheum Dis. 2007 Dec;66(12): 1675-8. Epub 2007 Jul 31.

49. Marotte H, MaslinskiW, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005;7(1): R149-55. Epub 2004 Dec 1.

50. Trocme C, Marotte H, Baillet A, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis. 2009 Aug;68(8):1328-33. doi: 10.1136/ard.2008. 093153. Epub 2008 Jul 29.

51. Fabre S, Dupuy AM, Dossat N, et al. Protein biochip array technology for cytokine profiles predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol. 2008 Aug;153(2):188-95. doi: 10.1111/j.1365-2249. 2008.03691.x. Epub 2008 Jun 18.

52. Hueber W, Tomooka BH, Batliwalla F, et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R76. doi: 10.1186/ar2706. Epub 2009 May 21.

53. Chen S, Deng C, Hu C, et al. Association of MCP-1-2518A/G polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Clin Rheumatol. 2016 May;35(5):1169-79. doi: 10.1007/s10067- 015-3060-5. Epub 2015 Aug 29.

54. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009 Jan;68(1):69-74. doi: 10.1136/ ard.2007.084715. Epub 2008 Mar 28.

55. Smeets TJ, Kraan MC, van Loon ME, et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003 Aug;48(8):2155-62.

56. Wang I, Chen WZ, Wu MP. Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index. Cytokine. 2010 Feb;49(2):194-200. doi: 10.1016/j.cyto.2009.08.008. Epub 2009 Oct 12.

57. Lequerre T, Gauthier-Jauneau AC, Bansard C, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 2006;8(4):R105.

58. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther. 2008;10(3):R50. doi: 10.1186/ar2419. Epub 2008 May 2.

59. Pachot A, Arnaud B, Marrote H, et al. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol. 2007 Nov;34(11):2158-61. Epub 2007 Sep 15.

60. Ostwald M, Curran ME, Lamberth SL, et al. Modular analusis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. Arthritis Rheumatol. 2015 Feb;67(2):344-51. doi: 10.1002/art.38947.

61. Kawashima M, Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet. And GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann Rheum Dis. 2005 Mar;64(3):415-8. Epub 2004 Jul 29.

62. Toh ML, Marotte H, Blond JL, et al. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum. 2006 Jul;54(7):2109-18.

63. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.

64. Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to infliximab in a large rheunatoid arthritis population. Ann Rheum Dis. 2006 Mar;65(3):342-7. Epub 2005 Aug 11.

65. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanecent therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3.

66. Padyukov I, Lampa J, Heimburger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003 Jun; 62(6):526-9.

67. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 2004 Apr;50(4):1077-82.

68. Pinto JA, Rego I, Rodriguez-Gomez M, et al. Polymorphisms in genes encoding tumour necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol. 2008 Jan;35(1):177-8.

69. Miceli-Ricard C, Comets E, Verdtuyft C, et al. A single tumor necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008 Apr;67(4):478-84. Epub 2007 Aug 2.

70. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid erthritis. Arthritis Rheum. 2003 Jul;48(7):1849-52.

71. Maxwell JR, PotterC, Hyrich KL, et al. Association of the tumour necrosis factor -308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008 Nov 15;17(22): 3532-8. doi: 10.1093/hmg/ddn245. Epub 2008 Aug 19.

72. Fonseca JE, Carvalha T, Cruz M, et al. Plymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis. 2005 May;64(5):793-4.

73. Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumour necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007 Dec 15;57(8):1426-30.

74. Seitz M, WirthmullerU, Moller B, et al. The -308 tumor necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007 Jan;46(1):93-6. Epub 2006 May 23.

75. Criswell LA, Lum RF, Turner K, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.

76. Balog A, Klauss G Gal J, et al. Investigation of the prognostic value of THF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology. 2004; 71(5):274-80.

77. Chatzikyriakidou A, Gerrgiou I, Voulgari PV, et al. Combined tumor necrosis factor-alpha and tumor necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford). 2007 Jun;46(6):1034-5. Epub 2007 Apr 4.

78. Constantin A, Dieude P, Lauwers-Cances V, et al. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum. 2004 Mar; 50(3):742-7.

79. Fabris M, Tolusso B, Di Poi E, et al. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol. 2002 Sep;29(9):1847-50.

80. Rooryck C, Barnetche T, Richez C, et al. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol. 2008 Mar-Apr;26(2):340-2.

81. Toonen EJ, Coenen MJ, Kievit W, et al. The tumor necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis. 2008 Aug;67(8): 1174-7. doi: 10.1136/ard.2008.088138. Epub 2008 Apr 2.

82. Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.

83. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. FC-gamma receptor type IIIA polymorphism influence treatment outcomes in patients with inflammatory arthritis treated with tumour necrosis factor alpha-blocking agents. Arthritis Rheum. 2005 Sep;52(9):2693-6.

84. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007 Mar;66(3):302-7. Epub 2006 Nov 1.

85. Raterman HG, Vosslamber S, de Ridder S, et al.The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

86. Ulfgren AK, Andersson U, Engstrom M, et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumour necrosis factor alpha synthesis. Arthritis Rheum. 2000 Nov;43(11):2391-6.

87. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expressionin the synovium. Ann Rheum Dis. 2008 Aug;67(8):1139-44. Epub 2007 Nov 29.

88. Buch MH, Reece RJ, Quinn MA, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford). 2008 Oct;47(10):1469-75. doi: 10.1093/rheumatology/ken261. Epub 2008 Jul 26.

89. Barrera P, Joosten LA, den Broeder AA, et al. Effects of treatment with fully human anti-tumour necrosis factor alpha monoclonal antibody on the focal and systemic homeostasis of interleukin 1and TNFalpha in patients with 1rheumatoid arthritis. Ann Rheum Dis. 2001 Jul;60(7):660-9.

90. De Groof A, Ducreux J, Humby F, et al. Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correclates with disease activity, and predicts absence of response to first line therapy. Arthritis Res Ther. 2016 Jan 20;18:19. doi: 10.1186/s13075-016-0919-z.

91. Lindberg J, af Klint E, Catrina AI, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther. 2006; 8(6):R179.

92. Badot V, Galant C, Nzeusseu Toukap A, et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R57. doi: 10.1186/ar2678. Epub 2009 Apr 23.

93. Scarsi M, Ziglioli T, Airo P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol. 2011 Oct;38(10):2105-11. doi: 10.3899/jrheum. 110386. Epub 2011 Aug 1.

94. Brezinschek HP, Rainer F, Brickmann K, et al. B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther. 2012 Jul 6;14(4):R161. doi: 10.1186/ar3901.

95. Scarsi M, Zanotti C, Chiarini M, et al. Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis. Clin Exp Rheumatol. 2014 Mar-Apr;32(2):204-10. Epub 2014 Jan 14.

96. Eftekhari P, Glaubitz L, Breidert M, et al. Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases. Dig Dis. 2014;32(4):446-54. doi: 10.1159/000358151. Epub 2014 Jun 23.

97. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis. 2008;67:563-6.

98. Schotte H, Schuter B, Willeke P, et al. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford). 2004;43:960-4.


Для цитирования:


Котовская М.А., Никишина Н.Ю., Олюнин Ю.А. Персонифицированная медицина: предикторы эффективности терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Современная ревматология. 2017;11(2):4-17. https://doi.org/10.14412/1996-7012-2017-2-4-17

For citation:


Kotovskaya M.A., Nikishina N.Y., Olyunin Y.A. Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis. Modern Rheumatology Journal. 2017;11(2):4-17. (In Russ.) https://doi.org/10.14412/1996-7012-2017-2-4-17

Просмотров: 461


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)